Ulixertinib Drug Asset Due Diligence Report 2026

This Ulixertinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Ulixertinib can convert its Small molecule drug profile and ERK1 x ERK2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Ulixertinib (query alias: Ulixertinib)
Modality / target	Small molecule drug; ERK1 x ERK2; ERK1 inhibitors, ERK2 inhibitors
Highest global status	Phase 2
Originator	Vertex Pharmaceuticals, Inc.
Active developers	Vertex Pharmaceuticals, Inc., National Cancer Institute, Eli Lilly & Co.

The MCP disease footprint includes Diffuse Large B-Cell Lymphoma, Hematologic Neoplasms, Histiocytoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06773195	Phase 1/2	Recruiting	37	Primary endpoint not disclosed in English source
NCT06411821	Phase 2	Recruiting	38	Primary endpoint not disclosed in English source
NCT06400225	Phase 2	Active, not recruiting	35	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

1641P - Activity of ulixertinib plus palbociclib in patients (Pts) with NRASQ61-mutant (mut) PD1 inhibitor refractory (PD1iR metastatic melanoma (MM))

Phase 1; n=9; evaluation: Positive. Reported fields: Adverse Event: RRAE = RRAE of any grade occurring in >=4 pts were rash, serum creatinine increase, fatigue, diarrhea, anemia, vomiting, thrombocytopenia, and neutropenia, resulting in dose reduction in 7 pts. Serious (grade >=3) RRAE occurring in >=3 patients were neutropenia and rash.

A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Phase 2; n=104; evaluation: Not stated in English source. Reported fields: Part A: Overall Response Rate (ORR) According to RECIST 1.1 = 0 Pts

Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial

Not disclosed; n=20; evaluation: Not stated in English source. Reported fields: PFS(6-month) = 37 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Ulixertinib addresses Diffuse Large B-Cell Lymphoma, Hematologic Neoplasms, Histiocytoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-07-29	Strata Oncology partners with BioMed to expedite patient identification for enrollment in the phase II study of BVD-523 for advanced solid tumors in the US.	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3k inhibitors having improved therapeutic index against solid tumors”. The milestone feed surfaced a patent-application signal described as “Methods for the detection and treatment of resistant cancers co-expressing ALPP and/or ALPG/alppl2”. The milestone feed surfaced a patent-application signal described as “Methods of treating cancer”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO